m d anderson cancer center

(University of Texas M. D. Anderson Cancer Center) M. D. Anderson researchers connect overexpression of tissue type transglutaminase with poor prognosis in ovarian cancer, identify the relevant pathway, and shut TG2 down with an siRNA liposomal nanoparticle.

They previously pinpointed TG2's role in resistant and metastatic melanoma and breast and pancreatic cancers.

This crucial protein fuels different cancers through different pathways.

(University of Texas M. D. Anderson Cancer Center) Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M.

D. Anderson Cancer Center reports in the July 3 edition of the New England Journal of Medicine.

(American Association for Cancer Research) People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the department of epidemiology at the University of Texas M.

D. Anderson Cancer Center.

(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas M. D. Anderson Cancer Center will advance two new therapeutic approaches for malignant brain tumors and develop biomarkers to guide treatment decisions under a major translational research grant from the National Cancer Institute.

(University of Texas M. D. Anderson Cancer Center) Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at the University of Texas M.

D. Anderson Cancer Center.

(University of Texas M. D. Anderson Cancer Center) A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a US phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston.

(University of Texas M. D. Anderson Cancer Center) Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at the University of Texas M.

D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.

(University of Texas M. D. Anderson Cancer Center) A poster session presented today by the University of Texas M.

D. Anderson Cancer Center at the Oncology Nurses Society 33rd Annual Congress, found that early nursing intervention and implementation of effective strategies can lead to a decrease in the incidence of lymphedema, better management of chronic lymphedema and improved quality of life in breast cancer patients.

(University of Texas M. D. Anderson Cancer Center) Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M.

D. Anderson Cancer Center.

(University of Texas M. D. Anderson Cancer Center) Researchers at the University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation.